论文部分内容阅读
目的分析异柠檬酸脱氢酶(IDH)1/2突变在低级别脑胶质瘤中与患者生存预后的相关性。方法通过焦磷酸测序的方法检测89例低级别脑胶质瘤样本中IDH1/2突变状态,分析IDH1/2突变在低级别脑胶质瘤中的发生频率,应用Kaplan-Meier生存曲线与单变量Cox比例风险回归模型分析IDH1/2突变与患者无进展生存期和总生存期的关系。结果有67例(75.3%)低级别脑胶质瘤样本存在IDH1突变,3例(3.4%)样本有IDH2突变。携带IDH1/2突变的低级别脑胶质瘤患者较IDH1/2野生型患者有较长的无进展生存期(P<0.05)和总生存期(P<0.01)。结论 IDH1/2突变在低级别脑胶质瘤中高频存在并可作为预后评估的生物学标志物。
Objective To analyze the association of isocitrate dehydrogenase (IDH) 1/2 mutations with the prognosis of patients in low-grade gliomas. Methods The mutation status of IDH1 / 2 in low grade gliomas was examined by pyrosequencing method. The frequency of IDH1 / 2 mutation in low grade gliomas was analyzed. Kaplan-Meier survival curves were compared with univariate Cox proportional hazards regression model was used to analyze the relationship between IDH1 / 2 mutation and progression-free survival and overall survival in patients. Results There were IDH1 mutations in 67 (75.3%) low grade gliomas and IDH2 mutations in 3 (3.4%) samples. Patients with low-grade gliomas carrying IDH1 / 2 mutations had longer progression-free survival (P <0.05) and overall survival (P <0.01) than IDH1 / 2 wild-type patients. Conclusion IDH1 / 2 mutation exists in low-grade glioma at high frequency and can be used as a biomarker for prognosis evaluation.